The addition of selumetinib to docetaxel failed to improve progression-free and overall survival in patients with KRAS-mutated locally advanced or metastatic NSCLC.
The oral PARP inhibitor rucaparib showed strong activity and an acceptable safety profile in women with high-grade, BRCA-mutated ovarian carcinoma who had previously received at least two lines of chemotherapy.
The oral PARP inhibitor niraparib yielded significantly improved progression-free survival for women with platinum-sensitive, recurrent ovarian cancer in a phase III trial.
Treatment with cabozantinib resulted in significantly improved PFS and overall response vs sunitinib for patients with metastatic renal cell carcinoma.
Use of the targeted therapy dabrafenib resulted in a high overall response rate and was well tolerated in a small phase I/II study of pediatric BRAF V600-mutant low-grade glioma.
Patients with renal cell carcinoma at high risk for recurrence had prolonged disease-free survival when treated with sunitinib compared with placebo.
The use of the PD1 inhibitor nivolumab appeared to be feasible and safe in a small study of patients with untreated, stage I–IIIa non–small-cell lung cancer.
A large percentage of patients with metastatic melanoma in Europe may not have access to innovative medicines used to treat the disease, according to the results of a survey.
Adding ribociclib, a CDK4/6 inhibitor, to letrozole significantly improved progression-free survival in postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.
Patients with working memory dysfunctions and depression may be more likely to be nonadherent to oral cancer therapies, according to the results of a study presented at ESMO.